Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | KCNQ4 | P56696 | 2/20 | 0.39 |
| ▸ | KCNQ5 | Q9NR82 | 2/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1646602 | 0.89 | AAK1 (0.52) | AAK1PRMT5WDR77CA1CA2 | |
| SCHEMBL3763011 | 0.88 | AAK1 (0.49) | AAK1PRMT5WDR77CA1CA2 | |
| SCHEMBL65546 | 0.86 | AAK1 (0.53) | AAK1PRMT5WDR77CA1CA2 | |
| SCHEMBL30931999 | 0.86 | AAK1 (0.50) | AAK1PRMT5WDR77CA1CA2 | |
| SCHEMBL4822133 | 0.85 | AAK1 (0.59) | AAK1PRMT5WDR77CA1CA2 | |
| SCHEMBL16156534 | 0.85 | PRMT5 (0.50) | AAK1PRMT5WDR77CA1CA2 | |
| SCHEMBL15882115 | 0.84 | AAK1 (0.48) | AAK1PRMT5WDR77BACE1BACE2 | |
| SCHEMBL15184583 | 0.84 | AAK1 (0.51) | AAK1PRMT5WDR77CA1CA2 | |
| SCHEMBL65967 | 0.84 | AAK1 (0.51) | AAK1PRMT5WDR77BACE1BACE2 | |
| SCHEMBL3562076 | 0.83 | AAK1 (0.48) | AAK1PRMT5WDR77CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12558428-B2 | Heterobifunctional compounds and their use in treating disease | HALDA THERAPEUTICS OPCO, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250281623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-09-11 | — | — | US | disclosed |
| US-20230219978-A1 | COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF | SCINNOHUB PHARMACEUTICAL CO., LTD (CN) | 2023-07-13 | — | — | US | disclosed |
| WO-2023078267-A1 | AMINO-CONTAINING MACROCYCLIC COMPOUND AS PROTEIN KINASE MODULATOR | 赛诺哈勃药业（成都）有限公司 | 2023-05-11 | — | — | WO | disclosed |
| EP-4163283-A1 | COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF | Scinnohub Pharmaceutical Co., Ltd (CN) | 2023-04-12 | — | — | EP | disclosed |
| WO-2022011274-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022011274-A1 | SUBSTITUTED 1,6-NAPHTHYRIDINE INHIBITORS OF CDK5 | GOLDFINCH BIO, INC. (US) | 2022-01-13 | — | — | WO | disclosed |
| US-10052330-B2 | Substituted pyrido[3,4-b]pyrazines as Syk inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2018-08-21 | — | — | US | disclosed |
| EP-2718293-B1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LTD (CN) | 2017-10-25 | — | — | EP | disclosed |
| EP-2718293-B1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LTD (CN) | 2017-10-25 | — | — | EP | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-08-14 | — | — | US | disclosed |
| WO-2003029209-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-10 | — | — | WO | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
| EP-1212327-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001072751-A1 | PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS | KNOLL GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2001-10-04 | — | — | WO | disclosed |
| EP-1114053-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2001-07-11 | — | — | EP | disclosed |
| WO-2001019829-A2 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2001-03-22 | — | — | WO | disclosed |
| WO-2000017203-A1 | PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153752-A1 | Pyrrolopyrimidines as therapeutic agents | FLT1, FLT4, TFPI | AAK1 871/4885PRMT5 652/4885WDR77 3864/4885 |
| US-12558428-B2 | Heterobifunctional compounds and their use in treating disease | BRCA1, H1-0, FOXM1 | AAK1 3871/4885PRMT5 457/4885WDR77 3550/4885 |
| US-20250281623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | VHL, HMBS, BRCA1 | AAK1 4035/4885PRMT5 1691/4885WDR77 3686/4885 |
| US-20230219978-A1 | COMPOUND HAVING MACROCYCLIC STRUCTURE AND USE THEREOF | BTK, SRC, YES1 | AAK1 1429/4885PRMT5 261/4885WDR77 2193/4885 |
| US-10052330-B2 | Substituted pyrido[3,4-b]pyrazines as Syk inhibitors | SYK, BTK, TYRO3 | AAK1 1660/4885PRMT5 221/4885WDR77 529/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | AAK1 2711/4885PRMT5 1816/4885WDR77 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.